Rp-hplc Peptide Pureness Evaluation
Rp-hplc Peptide Pureness Evaluation For peptides, contamination expectations follow a risk-based FDA technique, rather than the small-molecule limits in ICH Q3A/Q3B (which exclude peptides). Peptide-related impurities present at low-percent degrees (e.g., around 0.1% and over) typically require characterization, and higher-level or new contaminations might call for boosted validation because of potential immunogenicity issues. FDA guidance and ICH Q2( R1) aid specify needs fo